Investment Thesis — Repligen Corporation
The market overweights near-term bioprocessing demand softness and high valuation, missing Repligen’s structural leverage to next-gen biologics manufacturing. Current sentiment ignores the company’s unique positioning as a critical supplier for emerging modalities, which could drive outsized growth as industry bottlenecks resolve.
Catalysts
- Resolution of bioprocessing bottlenecks
- Regulatory approvals for cell and gene therapies
- Strategic partnerships with emerging biotech platforms
Risk Factors
- Extended industry demand softness
- Delayed adoption of new biologics modalities
- Customer concentration and execution missteps
Key Debates
Fwd P/E of 57x justified by 20% growth by H1 2025
RGEN rebounds to $150 by Q1 2025 on improving sentiment
Short covering drives 10% price rebound by year-end 2024